U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Financial PostAugust 19, 2026
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b data If approved, ecopipam would be the …
Where this sits on TrendsMap
This story hasn’t been tied to a specific state or province yet — it sits in our Canada coverage. We hold 2152 politics stories in total, and 1273 from Financial Post.
This is a summary of reporting by Financial Post. Read the full story at the source.
Read full storyPredictions (0)
No predictions yet on this story — be the first to start one.
Comments (0)
GU
posting as a guest
Create a free account to comment under your own name and earn Pulse.